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Abstract
Inflammatory myofibroblastic tumors (IMT) of the lung, first reported in 1939, are considered a subset of inflammatory pseudo
-tumors. They are a distinctive lesions composed of myofibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and eosinophils. IMTs may be benign, invade surrounding structures, undergo malignant transformation,
recur or may even metastasize. They can occur due to a genetic mutation or can occur secondary to infectious or autoimmune
diseases. Patients may be asymptomatic, or present with cough, hemoptysis, dyspnea, pleuritic pain, constitutional symptoms
or pneumonia. In this article we review the pathophysiology, genetics, clinical presentation, imaging findings of IMT of the lung.
We also discuss the various surgical and non-surgical treatment options and the prognosis associated with this disease.
Key words: inflammatory myofibroblastic tumor of the lung (IMT), inflammatory pseudo-tumor (IPT), pulmonary neoplasm, ALK,
bronchoscopy
Adv Respir Med. 2018; 86: 27–35

Introduction
Inflammatory pseudo-tumors (IPT) were first
described in 1905, in the orbital tissues of four
patients, with infiltration of the soft tissue with
lymphocytes [1]. They were labeled as ‘pseudo
-tumors’ because they clinically and radiologically mimicked malignancies [2]. Inflammatory
myofibroblastic tumors (IMT) of the lung, first
reported in 1939 [3], are considered a subset of
these IPTs. They are a distinctive lesions composed of myofibroblastic spindle cells accompanied
by an inflammatory infiltrate of plasma cells,
lymphocytes, and eosinophils [4].
IMTs account for 0.04 to 0.1% of all pulmonary neoplasms [5, 6]. They are more common
in children and are the most common pediatric
primary lung lesion [7, 8]. IMTs are usually benign

and resection achieves complete cure. However,
there are times when they invade surrounding
structures, undergo malignant transformation,
recur [9, 10] or may even metastasize [11, 12].
IMTs have been synonymously referred to
as pseudo-sarcomatous myo-fibroblastic or fibromyxoid lesion, plasma cell granuloma, fibrous
xanthoma, plasma cell pseudosarcoma, lymphoid
hamartoma, myxoid hamartoma, omental mesenteric myxoid hamartoma, inflammatory myofibrohistiocytic proliferation, benign myofibroblastoma, and inflammatory fibrosarcoma [4, 9, 13].

Pathophysiology and genetics
The exact pathophysiology and mechanism
of neoplasia in IMTs is unknown. Several genes
and chromosomal abnormalities have been found
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to be associated with IMTs. Anaplastic Lymphoma
Kinase (ALK) gene locus on 2p23 encodes a classical receptor tyrosine kinase (RTK) in mice and
humans. An ALK rearrangement is discovered
in approximately 40–50% of IMTs [14–17], but
more commonly in younger population [18].
ALK rearrangements produce fusion proteins that
constitutively activate tyrosine kinase, similar
to its action in anaplastic large-cell lymphoma,
diffuse large-cell lymphoma and non-small cell
lung cancer (NSCLC) [18, 19]. As will be described later, the ALK-RTK can be a target for newer
drug therapies.
ROS-1 is a receptor tyrosine kinase (RTK) of
the insulin receptor family. Chromosomal rearrangements involving the ROS-1 gene, on chromosome
6q22, were originally described in glioblastomas as
well as non-small cell lung cancers (NSCLC) [20].
Some IMTs without ALK rearrangement (ALK-negative) demonstrate ROS-1 gene fusions. One study
reported that 4/9 (44%) of ALK-negative tumors had
distinct ROS1 fusions [21]. There have been some
rare cases of IMT that have been negative for ALK
and ROS-1 mutations [22].
A subset of IMT lack ALK oncogenic activation but contain rearrangements targeting the
HMGIC (also known as HMGA2) gene on chromosome 12q15. Chromosomal aberrations involving
this region are very frequent among other benign
tumors, such as lipomas, uterine leiomyomas, or
pulmonary chondroid hamartoma [23]. There has
been a significant association between translocations in IMT and a high rate of aneuploidy [24],
the presence of which correlates well with local
recurrence and more aggressive biologic behavior
[13]. The presence of hyperdiploidy serves as an
indicator of the neoplastic nature of IMTs. Derivative of Chromosome (Der9) was reported in one
case of an omental-mesenteric IPT [25]. It was an
extra chromosome that evolved from a translocation between the long arm of chromosome 2 and
the short arm of chromosome 9 [(2; 9) (q1, 3; p2,
2)]. Other mutations such as PDGFR-b fusion have
also been reported in some IMTs [21].

Association with other diseases
Multiple infections including pulmonary
tuberculosis, pseudomonas lung infection, moraxella catarrhalis, actinomycetes, mycoplasma,
mycobacteria, Epstein-Barr virus and human
herpes virus 8 (HHV-8) have also been reported
with IPTs [10, 26–40].
Patients with autoimmune conditions such as
Sjörgen’s syndrome have also been reported to have
28

lung IMTs [41] and IPTs in choroid plexus [42],
liver [43] and pancreas [44]. In one patient with
lung IMT, concurrent B-cell lymphoma was seen
[9]. IgG4 syndrome [45, 46] has been reported with
IPTs; these tumors have been seen to form a subset of this syndrome. Pulmonary and extra-pulmonary IMTs have also been reported following
hematopoietic stem cell [47–49], graft versus host
disease [50] and solid-organ transplant [51–54].

Classification
The classification of IMTs is listed in Table 1.

Clinical features
They may be asymptomatic, or present with
cough, hemoptysis, dyspnea and pleuritic pain
[5, 56]. Systemic symptoms such as fever, weight
loss, malaise and fatigue can be seen in 15–30%
of patients. Some may present with recurrent
pneumonias [57, 58].

Imaging
Pulmonary IMTs occur more frequently in the
lower lobes with a predilection for peripheral lung
parenchyma and sub-pleural locations [7, 59].
On chest radiographs, pulmonary IMTs appear
as solitary, circumscribed, lobulated lesions preferentially localized to the lower lobes, occasionally with pleural effusions (Fig. 1) [56]. When
IMT presents as a solitary pulmonary nodule, the
main radiologic differential diagnosis includes
a primary or secondary neoplasm, hamartoma,
hemangioma, chondroma, and pulmonary sequestration [60, 61].
On computed tomographic (CT) scans, inflammatory pseudotumors have a variable and
nonspecific appearance, but most commonly
they appear with heterogeneous attenuation
and enhancement (Fig. 2A–C). On T1-weighted
magnetic resonance (MR) images, these tumors
have intermediate signal intensity and high
signal intensity on T2-weighted images [60].
Calcification within the lesion occurs more
frequently in children than in adults (Fig. 2A, B).
The pattern of calcification can range from an
amorphous, mixed, or fine fleck-like pattern to
heavy mineralization.
IMTs can be discovered bilaterally, with
endobronchial lesions causing atelectasis and
in the pulmonary arteries [60, 62–64]. IMTs may
show uptake of fluorodeoxyglucose; and it may be
used to monitor response to therapy [62, 65, 66].
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Table 1. Classification of IMT’s
(A) Earliest classification by Cerfolio et al. [5]
Non-invasive IPT

Invasive IPT

Asymptomatic patients

Younger patient with systemic symptoms of fever, fatigue, or weight loss

Small lesions that do not invade surrounding
structures

It is large and may invade local mediastinal structures or the chest wall
Grossly, it is an invasive tumor that grows through tissue planes
Pathologically, it is characterized by nuclear atypia and a high number of mitotic figures

Usually easily removed by wedge resection

Usually requires a lobectomy or pneumonectomy for complete removal and may also
require a concomitant chest wall resection

(B) Classification by Matsubara et al. [55]
Organizing pneumonia

Fibrous histiocytoma

Lymphoplasmacytic

Intra-alveolar lymphohistiocytic inflammation
converting peripherally to intra-alveolar fibrosis and centrally to interstitial fibrosis (because of fibroblasts proliferation)

Predominant spindle cell proliferation, histiocytes in a storiform pattern and loss of the
alveolar architecture

Predominant lymphocytes and plasma
cells with little fibrosis

(C) 3 basic variants of IMT [4] as per WHO classification of soft tissue tumors
Resembling nodular fasciitis

Resembling fibrous histiocytoma or fibromatosis

Resembling scar or desmoid tumor

Loosely organized myofibroblasts in an
edematous myxoid background with plasma
cells, lymphocytes, eosinophils, and blood
vessels

Dense aggregates of spindle cells arrayed in
a variable myxoid and collagenized background admixed with a distinctive inflammatory
infiltrate, diffuse clusters of plasma cells, and
lymphoid nodules

Collagen sheets with scattered plasma
cells and eosinophils

Figure 1. Chest X-ray showing well circumscribed right lower lobe
lesion

Interestingly, a positive uptake in 111 In-Diethylene triamine pentaacetic acid (DTPA)-D-Phe1
scan (Octreoscan) has been described implying
response to somatostatin analogue receptors [67].

Associated serum biochemistry
and histopathology
Laboratory evaluation may reveal microcytic
anemia; increase in acute phase reactants such as

erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); thrombocytosis and polyclonal
hypergammaglobulinemia. These findings have
been attributed to overproduction of interleukin
(IL)-6 [39, 57, 68].
On biopsy, the predominant cells seen are
spindle cells. They are seen as interlacing fascicles among a polymorphous inflammatory
infiltrate consisting of mature plasma cells and
small lymphocytes [10, 12]. Spindle cell proliferation is noted to be more marked in IMT, whereas
lymphoplasmacytic infiltration is more prominent
in IPTs [69]. An example of histopathology slides
including immunohistochemistry from a patient
with IMT is demonstrated in the attached figures
(Fig. 3, 4A, B, 5–7]. On immunohistochemistry
(IHC), virtually all IMTs show reactivity for
vimentin. The reactivity for smooth muscle actin and muscle specific actin varies in pattern.
Desmin and focal cytokeratin immunoreactivity
is identified in some cases. Myogenin, myoglobin,
and S100 protein are negative [4, 12].
ALK expression may be negative by IHC;
rearrangement for ALK locus by fluorescence in
situ hybridization (FISH) may be required [39]
or newer IHC methods may have to be adopted
[70]. Another difference between IPTs and IMTs
is that on the basis of IHC and FISH characteri-
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A

B

Figure 3. Low magnification image showing extension of the tumor
extending to the visceral pleura indicated by the black arrows

hyaluronan as a surrogate marker that correlated
with changes in the IMT [14]. This needs further
investigation.

Treatment
Surgery is considered the mainstay of treatment. If complete resection is not possible, due to
anatomic location or co-morbidities, then medical
therapy in conjunction with radiation therapy
could be considered.

C

Surgery

Complete surgical resection, when possible,
is the best method for diagnosis and treatment
[56, 61] (Fig. 4A, B). Lobectomy and pneumonectomy should be performed if required for complete cure. A recurrence rate of 8% was reported
with a primarily surgical approach. However, it is
unclear if the recurrence was local or distant [9].

Figure 2A–C. Computed tomography of the chest showing a mass in
the right lower lobe with interspersed calcification

stics, IMTs have not been found to always be IgG4
related [46]. As seen later, this fact may explain
the response to steroids.
Prior to surgery, it is recommended to have
liver function testing, pulmonary function testing
and staging CT scans of the chest and upper
abdomen. This helps to evaluate for concurrent
IPTs/IMTs in other parts of the body [5]. Since
morphological features do not predict biologic
behavior, and the ploidy of the tumor needs to
be determined [13]. One study reported serum
30

Bronchoscopy and endobronchial
resection

Rigid bronchoscopy and endobroncial resection (by surgical excision or laser) has been
successful for IMTs confined to the trachea and
smaller airways [71–74]. In some cases, this has
been combined with use of steroids, with mixed
results [75]. These patients should also be followed closely and may require more extensive
surgery if persistence of the lesion is seen [76].

Chemotherapy

Chemotherapy is useful in cases of multifocal,
invasive lesions or in cases of local recurrence [77].
Carboplatin and Paclitaxel have been reported to be
useful in some cases [78], but this response does
not appear to be generalizable to all cases [79].
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A

Figure 5. Black arrows represent myofibroblastic cells: spindle cells
with long cytoplasmic processes which are characteristic in IMT.
White arrows pointing to plasma cells with characteristic perinuclear
cytoplasm which are often seen in IMT

B

Figure 4A, B. Histopathology of the tumor demonstrating spindle cells

Steroids

The use of steroids for IMTs is controversial.
They were initially recommended to reduce
surrounding inflammation, particularly in CNS
IMTs [9]. IMT response to steroid therapy [68, 80]
and steroids along with antibiotics [10], has
been well-documented. One case of recurrent
IPT, 11 years after steroid therapy, responded
to repeat steroid therapy [25]. Some believe
that the cases of IPTs/IMTs that responded to
steroids could be based on the fact that they
are IgG4-related, and this needs to be confirmed with histopathology [81]. However, other
studies have reported worsening of IMT with
steroids [82, 83]. Moon et al. [83] reported aggravation of pulmonary and bone metastases, as
evident by radiologic worsening on bone scan
and CT scan, as well as increased fibroblastic
cell proliferation in cultures, in the presence
of dexamethasone. However, we need larger
studies to make determination of the efficacy
of steroids for IMTs.

Figure 6. Arrows represent infiltrative inflammatory cells around
a bronchiole that shows mucus plugging with inflammatory cells

Non-steroidal anti-inflammatory drugs
(NSAIDs)

NSAIDs like Celecoxib have been used for
some cases of histologically-proven IMT that are
negative for ALK and ROS-1 mutations [22, 84].
This was based on the hypothesis that NSAIDs
inhibit cyclo-oxygenase-2 (COX-2) enzyme and
vascular endothelial growth factor (VEGF) signaling, thus interfering with angiogenesis. It was
also observed that the level of ALK positivity in
these cases did not correlate with the intensity
of COX-2 or VEGF staining [85].

ALK RTK inhibitors and ROS-1 TK
inhibitors

ALK RTK inhibitors (Crizotinib, Alectinib
and Ceritinib) have been noted to be effective for
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Figure 7. ALK and desmin staining of histopathologic sample

with chemotherapy, there is currently no evidence
to support routine use of radiotherapy in patients
who have complete resection.

Prognosis

Figure 8. Gross pathology sample of a surgically removed IMT from
a young adult

extra-pulmonary [86–88] and pulmonary IMTs
[15]. They may be effective agents for patients with
advanced or potentially unresectable ALK-rearranged IMTs, regardless of the location of the primary
lesion [15]. Crizotinib has also proven to be effective in IMTs harboring ROS1 kinase fusions [21, 89].

Radiation

Radiation treatment has been shown to be of
some benefit in pulmonary IMT [90, 91]. Failures
of radiation therapy have, however, been reported
suggesting that surgical excision should be primary therapy [81]. Radiation is typically reserved for
palliation, to alleviate the mass effect of the IMT,
or in conjunction with chemotherapy for cure in
patients who are not amenable to resection [9]. As
32

Pulmonary IMT, if left untreated has shown
an approximately 8% rate of growth on follow-up
studies. In some cases of pulmonary IMT, spontaneous resolution has also been observed [92–94].
Prognosis is excellent after radical surgical excision, with 5-year survival rates greater than 91%
[5, 95–97]. Patients who underwent complete
resection showed better survival rates [12]. One
study reported a 60% recurrence rate in those
receiving incomplete resection [5]. Interestingly,
IPTs confined to the lung recurred less frequently
than extra-pulmonary IPTs; but, if the IPT spread
outside the lung, it recurred more frequently than
extra-pulmonary IPTs that had spread to different
organs [98].
A combination of cellular atypia, ganglion-like cells, TP53 expression, and aneuploidy may
help to identify IMT with a more aggressive potential [4]. ALK-positive IMT is associated with better
prognosis than ALK-negative IMT, as ALK-negative
is associated with higher rate of metastasis and resistance to therapy [69]. Pulmonary IMT patients
should have long-term follow up, due to the risk
of recurrence and sarcomatous transformation
[99]. Sarcomatous transformation has also been
noted in extrapulmonary tumors [100].

Conclusion
Inflammatory myofibroblastic tumors (IMT)
of the lung are a distinctive lesion composed of

www.journals.viamedica.pl

Akshay Khatri et al., Inflammatory myofibroblastic tumor of the lung

myofibroblastic spindle cells accompanied by an
inflammatory infiltrate of plasma cells, lymphocytes, and eosinophils. IMTs may follow a benign
course, be locally invasive or metastasize. Patients
may be asymptomatic, or present with cough, hemoptysis, dyspnea, pleuritic pain, constitutional
symptoms or pneumonia. Diagnosis is predominantly made using various imaging modalities
and with histological confirmation. Genetic testing should also be conducted to assess for the
possibility or targeted adjuvant therapies. Primary
treatment of choice is surgical resection as well
as chemotherapy. Though rare, IMT should be on
the differential in patients who clinically present
with signs and symptoms of lung mass.
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